Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib +/- defactinib in recurrent LGSOC
NCT04625270Phase 2Active, not recruiting
- Sponsor
- Verastem Oncology
- Start
- Dec 2020
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of avutometinib in Low grade serous ovarian cancer (LGSOC), sponsored by Verastem Oncology. Started Dec 2020; status: active, not recruiting.
02
Drugs
avutometinib
03
Conditions
Low grade serous ovarian cancer (LGSOC)
Beyond the preview
Go deeper on NCT04625270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04625270.